

Effect of Probiotics on the levels of Neuroendocrine Biomarkers – A Systematic Review and Meta-Analysis

Manav Jain MD¹, Aishwarya Anand PhD², Nisha Sharma PhD³, Muhammad Aaqib Shamim MBBS⁴, Elena Enioutina MD PhD¹

¹Division of Clinical Pharmacology Department of Pediatrics, ²Department of Pediatrics, ³Department of Pharmacology, ⁴Department of Pharmacology

¹Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, UT, USA, ²University of Maryland School of Medicine, Baltimore, MD, USA, ³Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India, ⁴ All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.

INTRODUCTION

- Gut microbiota influences brain function through immune modulation, neurotransmitter production, and direct effects on the HPA axis¹
- Probiotics are explored for their potential benefits in conditions such as depression, anxiety, PCOS, autism, cognitive impairment, obesity, and stress²⁻⁴
- They may affect levels of bioactive substances, including hormones and inflammatory, immunological, and oxidative markers²


OBJECTIVE

Assess the effect of probiotics on neuroendocrine biomarkers (cortisol, BDNF, DHEA, AA, ACTH, oxytocin, norepinephrine, and epinephrine)

METHODLOGY

- Protocol: PROSPERO (CRD42024538539)
- Data Sources: Searched seven databases from inception to March 18, 2024
- Inclusion Criteria: Participants across all age groups; no specific medical condition order requirement; probiotics given as a standalone or as a part of a combination therapy; Placebo, routine care or any active comparator other than probiotics, randomized controlled trials
- Pooled estimate: Standardized mean difference (SMD) with 95% confidence interval (CI) for each biomarker
- Random-effects model, heterogeneity assessed with I² and 95% prediction interval
- Subgroup analyses population (diseased or healthy), treatment duration $(\le 6 \text{ or } > 6 \text{ weeks})$, number of strain $(\le 1 \text{ or } > 1)$, presence or absence of concomitant medications, and region
- Sensitivity analysis leave-one-out meta-analysis, and outlier detection.
- **Publication bias** detected using contour-enhanced funnel plots and Egger's regression (p<0.1)
- Analyses performed in R software (v4.3.0)
- Quality assessment using Cochrane Risk of Bias 2.0 tool
- Certainty of evidence assessed with GRADE methodology

RESULTS






Table 1. Summary of analysis for all the biomarkers

- Table 1. Summary of amarysis for all the biomarker
- Figure 1. PRISMA Flow Chart




Figure 2. Forest Plot - Cortisol




Figure 3. Funnel Plot - Cortisol

- Screening through 6700 records yielded 43 RCTs, including 3220 participants (Figure 1).
- Probiotics did not cause significant alterations in biomarker levels when all studies were analysed collectively for each outcome measure, but high heterogeneity rendered the evidence inconclusive (Table 1, Figure 2, 3).
- On subgroup analyses, heterogeneity remained very high in each subgroup for every outcome.
- Following sensitivity analyses, a considerable reduction in heterogeneity and narrowing of CI was observed, resulting in the inclusion of 19 studies for cortisol, 7 for BDNF, and 5 each for DHEA and AA in the final analysis (**Table 1**).
- Probiotics did not alter any biomarker levels significantly.
- The certainty of the evidence was high for cortisol, BDNF, and DHEA, AA, and very low for oxytocin and ACTH in this analysis.

DISCUSSION & CONCLUSION

- Probiotics do not significantly alter neuroendocrine biomarker levels
- High heterogeneity indicated wide differences among the studies included, subgroups specified a *priori* failed to address heterogeneity in our analysis, indicating additional unmeasured factors involvement.
- Our results agreed to the previous findings, except for BDNF where a few subgroups showed increase levels²⁻⁵
- Evidence remains inconclusive for oxytocin and ACTH due to limited data availability

IMPACT OF RESEARCH

- Challenges previous findings on probiotics modulating cortisol, BDNF, DHEA, and AA levels in various diseases
- Need for more targeted studies to identify specific conditions or subpopulations where probiotics may have beneficial effects
- Potential to guide future clinical recommendations for probiotic use

REFERENCES

- 1. Rusch JA et al. Front Endocrinol. 2023;14:1130689
- 2. Sikorska M et al. *Int J Mol Sci*. 2023;24(4)
- 3. Zhang N et al. *Brain Behav.* 2020;10(9):e01699
- 4. Deghani et al. Nutr Neurosci. 2023;26(10):942-52
- 5. Tabrizi et al. Probiotics Antimicrob Proteins. 2022 Feb;14(1):1-14